Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells - 24/08/11


Créteil and Paris, France
Résumé |
Background |
Toxic epidermal necrolysis (TEN) is a very rare but extremely severe drug reaction characterized by widespread apoptosis of epidermis with extensive blisters. We previously found drug-specific cytotoxic CD8 T lymphocytes in the blisters of a single patient.
Objective |
To confirm the role of drug specific cytotoxic lymphocytes in a larger series, to test the cytotoxicity on keratinocytes, and to look for cross-reactivity between chemically related drugs.
Methods |
The phenotype of lymphocytes present in the blister fluids of 6 patients with TEN was analyzed by flow cytometry. Cytotoxic functions were tested by chromium release assay on a variety of target cells (autologous or MHC class I–matched EBV-transformed lymphocytes, autologous keratinocytes) after nonspecific (CD3 monoclonal antibody) or specific (suspected and potentially cross-reactive drugs) activation.
Results |
Blister lymphocytes were CD8+HLA-DR+CLA+CD56+. In all 6 cases, they were cytotoxic after nonspecific activation. A drug-specific cytotoxicity was observed in 4 cases (3 related to cotrimoxazole and 1 to carbamazepine) toward lymphocytes. Blister cells also killed IFN-γ–activated autologous keratinocytes in the presence of drug in the 2 patients tested. Blister cells showed a strong immunoreactivity for granzyme B, and cytotoxicity was abolished by EGTA, but not by anti-Fas/CD95, suggesting perforin/granzyme–mediated killing.
By using several sulfonamides for testing the specificity of the drug T-cell receptor interaction, we observed cross-reactivity only between 4 structurally closely related medications.
Conclusion |
These results strongly suggest that drug-specific, MHC class I–restricted, perforin/granzyme–mediated cytotoxicity probably has a primary role in TEN.
Le texte complet de cet article est disponible en PDF.Key words : Toxic epidermal necrolysis, drug hypersensitivity, cytotoxic T lymphocytes, MHC, keratinocytes
Abbreviations used : CLA, CTL, EGTA, E/T, SMX, SMX-NO, SMX-NOH, TCR, TEN, TMP, TMP-SMX
Plan
Supported in part by a grant from the French Ministry of Health (No AOM 98027) and through contracts between Institut National de la Santé Et de la Recherche Médicale and the following drug companies: Bayer, Glaxo-Wellcome, Hoechst-Marion-Roussel, Leo, Lilly, Novartis, Parke-Davis-Jouveinal, Pfizer, Rhone-Poulenc-Rorer, Sanofi-Winthrop, and Servier. Dr Nassif was the recipient of grants from Fondation pour la Recherche Médicale and Société pour l'Investigation Dermatologique Et Allergologique. Dr Moslehi received a grant from the Fondation René Touraine. |
Vol 114 - N° 5
P. 1209-1215 - novembre 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?